In the evolving field of peptide chemistry, few compounds have garnered as much interest as AXT107 peptide. As someone who follows the latest advancements in synthetic biology and biomimetic research, I have spent considerable time analyzing the structural and functional properties of this unique molecule. Often referred to by its generic name, Gersizangitide, this compound represents a fascinating intersection of structural biology and vascular stabilization research.
Understanding the Structural Mechanism of AXT107
At its core, AXT107 is a collagen IV-derived peptide consisting of 20 amino acids. Unlike standard signaling m First patient dosed in AXT107 clinical trial for DME olecules, this synthetic peptide is designed to function as a mimetic, specifically engineered to interact with complex biological pathways.
The primary mechanism that makes AXT107 stand out is its ability to bind to integrins, specifically αvβ3 and α5β1, with exceptionally high affinity. By binding to these integrins, the peptide effectively disrupts the VEGFR2-β3 complex. This is a crucial distinction from traditional inhibitors, as it allows the molecule to exert control over vascular signaling p Treatment of age-related visual impairment with a peptide acting on athways—specifically by blocking pro-angiogenic VEGF signals while simultaneously promoting vascular stabiliza Gersizangitide - AsclepiX Therapeutics - AdisInsight tion through Tie2 activation.
Why AXT107 Peptide is a Subject of Intense Scientific Study
From a researcher’s perspective, the interest in this compound stems from its multi-pathway interference. While many conventional agents target only VEGF, AXT107 interferes with three distinct signaling pathways that underlie blood vessel growth: VEGFR2, c-Met, and PDGFRβ.
This "one-two punch" approach is what researchers describe when discussing how it stops abnormal blood vessels in the eye from leaking vision-blocking fluids. By resolving TNFα-induced vascular inflammation in endothelial cells, the peptide acts as a regulator, converting endogenously released Ang2 into an agonist of Tie2 signaling. This dual-action mechanism is why it is often categorized as a "Gel Forming Peptide," providing a sustained release profile that is highly desirable in long-term observational studies.
Key May 5, 2024—The goal of this clinical trial is to understand the safety ofAXT107injected suprachoroidally in participants with nAMD.Read more Observations and Data Points
Based on the available documentation, here are the technical specifications that define this molecule:
* Classification: Collagen IV-derived, anti-angiogenic peptide.
* Molecular Target: Integrins αvβ3 and α5β1 (Kd=1.29 and 2.21 nM).
* Primary Function: Inhibits VEGFR2 signaling and activates Tie2.
* Clinical Potential: Investigational studies have explored AXT107 0.1 mg/eye as a potential dosage for evaluating biological activity.
Furthermore, the data suggests that AXT107 is safe for intravitreal injection, with some studies indicating that its structural stability could support potentially once-a-year dosing in clinical settings. This longevity is a significant improvement over existing therapies that require much more frequent administration.
Personal Perspective on Peptide Research
My interest in AXT107, a collagen-derived peptide, is purely academic. In the world of peptide research, it is vital to distinguish between commercial supplements and advanced investigational drug candidates like AXT-107. Because it is a highly specialized molecule, it is not a "lifestyle" peptide but rather a sophisticated tool for understanding vascular physiology.
When reviewing the literature on AXT107, a collagen IV-derived peptide, one cannot help but be imp May 6, 2024—AsclepiX's lead clinical candidate,integrin regulating peptide AXT107, has a novel mechanism of action that inhibits neovascularization Read more ressed by the precision of its design. By targeting the root causes of vascular leakage—rather than just the symptoms—this integrin regulating peptide AXT107 sets a high bar for future synthetic biology.
Final Thoughts
Whether you are following the progress of AsclepiX Therapeutics or simply interested in how AXT107 inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2), it is clear that this molecule is at the forefront of modern biochemistry. The ability of AXT107 to restore healthy, non-leaky vasculature is a testament to the power of mimicking natural collagen structures to solve complex biologica Jan 18, 2017—AXT107-injected or aflibercept-injected eyes. This tinypeptidemay form the basis of a new generation of drugs that augment current Read more l challenges. As research continues to advance, the role of this tyrosine kinase blocking collagen IV-derived peptide will undoubtedly r Clinical Trial Update January 2026 emain a cornerstone of vascular stabilization studies.
*Disclaimer: Thi Safety and Bioactivity of AXT107 in Subjects With s article is for informational purposes based on publicly available research and does not constitute medical advice or recommendations for human use.*